Literature DB >> 18760281

Rapid identification and sorting of viable virus-reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137 expression.

Thomas C Wehler1, Michael Karg, Eva Distler, Abdo Konur, Marion Nonn, Ralf G Meyer, Christoph Huber, Udo F Hartwig, Wolfgang Herr.   

Abstract

Current methods for the detection and isolation of antigen-specific CD4(+) and CD8(+) T cells require the availability of peptide/MHC multimers or are restricted to cells that produce cytokines after antigen contact. Here we show that de novo cell surface expression of the TNF-receptor family member CD137 (4-1BB) identifies recently activated, but not resting, human CD4(+) and CD8(+) memory T cells. Maximum CD137 expression level is uniformly observed in both T-cell subsets at 24h after stimulation with antigen. In experiments with CMV and EBV-reactive T cells, we confirmed the specificity of CD137 expression by co-staining with peptide/HLA tetramers. Substantial proportions of CD137(+) T cells did not produce IFN-gamma, suggesting that CD137 detects a broader repertoire of antigen-specific T cells. Activated CD137(+) T cells could be easily purified by MACS and expanded in vitro thereafter. This CD137-based enrichment method was capable of isolating 2-fold higher numbers of anti-viral CD4(+) and CD8(+) T cells compared to the IFN-gamma secretion assay. In conclusion, antigen-triggered CD137 expression allows the rapid detection and sorting of virus-reactive CD4(+) and CD8(+) T cells. The CD137 assay is most attractive for the simultaneous targeting of anti-viral T helper and effector cells in monitoring studies and adoptive immunotherapy trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18760281     DOI: 10.1016/j.jim.2008.07.017

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  28 in total

Review 1.  T-cell recognition of chemicals, protein allergens and drugs: towards the development of in vitro assays.

Authors:  Stefan F Martin; Philipp R Esser; Sonja Schmucker; Lisa Dietz; Dean J Naisbitt; B Kevin Park; Marc Vocanson; Jean-Francois Nicolas; Monika Keller; Werner J Pichler; Matthias Peiser; Andreas Luch; Reinhard Wanner; Enrico Maggi; Andrea Cavani; Thomas Rustemeyer; Anne Richter; Hermann-Josef Thierse; Federica Sallusto
Journal:  Cell Mol Life Sci       Date:  2010-08-18       Impact factor: 9.261

2.  p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.

Authors:  Nicola R Hardwick; Paul Frankel; Christopher Ruel; Julie Kilpatrick; Weimin Tsai; Ferdynand Kos; Teodora Kaltcheva; Lucille Leong; Robert Morgan; Vincent Chung; Raechelle Tinsley; Melissa Eng; Sharon Wilczynski; Joshua D I Ellenhorn; Don J Diamond; Mihaela Cristea
Journal:  Clin Cancer Res       Date:  2018-01-04       Impact factor: 12.531

3.  p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses.

Authors:  Nicola R Hardwick; Mary Carroll; Teodora Kaltcheva; Dajun Qian; Dean Lim; Lucille Leong; Peiguo Chu; Joseph Kim; Joseph Chao; Marwan Fakih; Yun Yen; Jonathan Espenschied; Joshua D I Ellenhorn; Don J Diamond; Vincent Chung
Journal:  Clin Cancer Res       Date:  2014-07-01       Impact factor: 12.531

4.  Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.

Authors:  Sanja Stevanović; Lindsey M Draper; Michelle M Langhan; Tracy E Campbell; Mei Li Kwong; John R Wunderlich; Mark E Dudley; James C Yang; Richard M Sherry; Udai S Kammula; Nicholas P Restifo; Steven A Rosenberg; Christian S Hinrichs
Journal:  J Clin Oncol       Date:  2015-03-30       Impact factor: 44.544

5.  Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine.

Authors:  Lichen Jing; Jürgen Haas; Tiana M Chong; Joseph J Bruckner; Greg C Dann; Lichun Dong; Joshua O Marshak; Christopher L McClurkan; Tori N Yamamoto; Susanne M Bailer; Kerry J Laing; Anna Wald; Georges M G M Verjans; David M Koelle
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

6.  Protective HIV-specific CD8+ T cells evade Treg cell suppression.

Authors:  Shokrollah Elahi; Warren L Dinges; Nicholas Lejarcegui; Kerry J Laing; Ann C Collier; David M Koelle; M Juliana McElrath; Helen Horton
Journal:  Nat Med       Date:  2011-07-17       Impact factor: 53.440

7.  Phenotype and functional evaluation of ex vivo generated antigen-specific immune effector cells with potential for therapeutic applications.

Authors:  Shuhong Han; Yuju Huang; Yin Liang; Yuchin Ho; Yichen Wang; Lung-Ji Chang
Journal:  J Hematol Oncol       Date:  2009-08-06       Impact factor: 17.388

8.  Multiparameter flow cytometry for discovery of disease mechanisms in rheumatic diseases.

Authors:  Mark J Soloski; Francis J Chrest
Journal:  Arthritis Rheum       Date:  2013-05

9.  The role of CD4(+) T cells in BKV-specific T cell immunity.

Authors:  B J D Weist; M Schmueck; H Fuehrer; A Sattler; P Reinke; N Babel
Journal:  Med Microbiol Immunol       Date:  2014-07-23       Impact factor: 3.402

10.  Activation-induced CD137 is a fast assay for identification and multi-parameter flow cytometric analysis of alloreactive T cells.

Authors:  N H R Litjens; E A de Wit; C C Baan; M G H Betjes
Journal:  Clin Exp Immunol       Date:  2013-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.